Human IFN-γ(Interferon Gamma) ELISA Kit
中文名称:人γ干扰素(IFN-γ)酶联免疫吸附测定试剂盒
别称:
IFNG、IFG、IFI、Type II Interferon
Price:
Size:
96T
48T
96T*5
- 反应性: Human
- 检测范围: 15.63-1000 pg/mL
- 灵敏度: 9.38 pg/mL
产品应用 | ELISA |
检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗人IFN-γ抗体包被于酶标板上,实验时样品(或标准品)中的人IFN-γ会与包被抗体结合。后依次加入生物素化的抗人IFN-γ抗体和辣根过氧化物酶标记的亲和素,抗人IFN-γ抗体与结合在包被抗体上的人IFN-γ结合,生物素与亲和素特异性结合而形成免疫复合物,游离的成分被洗去。加入显色底物(TMB),TMB在辣根过氧化物酶的催化下呈现蓝色,加终止液后变成黄色。用酶标仪在450 nm波长处测OD值,IFN-γ浓度与OD450值之间呈正比,通过绘制标准曲线计算出样品中IFN-γ的浓度。 |
反应类型 | Sandwich-ELISA |
规格 |
96T
/ 48T
/ 96T*5
|
反应时间 | 3.5h |
反应性 | Human |
检测方法 | 比色法 |
检测范围 | 15.63-1000 pg/mL |
灵敏度 | 9.38 pg/mL |
样本体积 | 100μL |
样本类型 | 血清,血浆,细胞上清,细胞提取液体,组织匀浆等其他生物体液 |
特异性 | 可检测样本中的人IFN-γ,且与其它类似物无明显交叉反应 |
精密度 | 板内,板间变异系数均<10% |
回收率 | 80%-120% |
储存条件 | 2-8℃/-20℃ |
数据处理 |
-
Can the Prognosis of COVID-19 Disease Be Determined by Fecal Markers and Cytokines?
IF: 3.657 -
The positive feedback loop of furin and TGFβ1 enhances the immune responses of Tregs to hepatocellular carcinoma cells and hepatitis B virus in vitro
IF: 3.612 -
Genetic Polymorphisms of IFNG, IFNGR1, and Androgen Receptor and Chronic Prostatitis/Chronic Pelvic Pain Syndrome in a Chinese Han Population
IF: 3.434 -
MiRNA505/NET1 Axis Acts as a CD8+ T-TIL Regulator in Non-Small Cell Lung Cancer
IF: 3.337Journal:OncoTargets and Therapy -
Systemic and local cytokine profile and risk factors for persistent allergic airway inflammation in patients sensitised to house dust mite allergens
IF: 3.317 -
Evaluation of IL-10, IFN-γ, and thiol–disulfide homeostasis in patients with drug-resistant epilepsy
IF: 3.307Journal:NEUROLOGICAL SCIENCES -
Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma
IF: 3.269 -
Regulatory Effects of Fyn on Trophoblast Cell Behaviors and Function
IF: 3.246 -
Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis
IF: 3.115Journal:JOURNAL OF THE NEUROLOGICAL SCIENCES -
A role for serum cytokines and cell adhesion molecules in the non‑invasive diagnosis of colorectal cancer
IF: 3.111Journal:Oncology Letters